Learn more about investing in Karma Biotech

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
Karma Biotech
Delivering cytokines and other biologicals locally, exactly where they're needed
* Data source: Crunchbase
Funding to Date*
* Data source: Crunchbase
CEO Andrew Gray, PhD
"Macrophages are so good at homing to tumors that they end up being 50% of the tumor mass. We're exploiting that to infiltrate tumors and deliver our biological drugs behind enemy lines."
Metastatic cancer can be cured by cytokine immunotherapies, but only for a lucky few (about 7% of patients). Karma is making these medicines safe and effective for the other 93%.

Karma Biotech is an oncology company targeting solid tumors, starting with colorectal cancer. Their technology aims to deliver cytokines and other biologicals, such as IL-15, specifically to tumor and metastatic sites, avoiding the dangers of systemic toxicity. This localized IL-15 will turn cold tumors hot, allowing the body to clear the cancer. 

The founders at Karma rationally designed super stable LNPs that are effective at delivering both DNA and/or RNA without electroporation. Their proprietary LNPs efficiently transfect macrophages in the spleen – which then home to tumor sites and produce the payload (e.g., IL-15) at the tumor microenvironment. This is one of the most elegant methods we’ve seen at fighting hard-to-penetrate solid tumors. While they’re quickly advancing through their own internal drug program, they can also generate some early revenue by partnering out with other pharma companies who have already been impressed by Karma’s latest data package (summer 2023).